Search PubMedSearch

Biomedical subjects

M J Shaffer

Publications and source records attributed to M J Shaffer.

At least 19 recordsLinked to original sources

Autoradiographic identification of brain angiotensin IV binding sites and differential c-Fos expression following intracerebroventricular injection of angiotensin II and IV in rats.

A unique angiotensin binding site specific for the hexapeptide, angiotensin II(3-8) (AngIV), has been previously reported by our laboratory in the guinea pig brain and is presently described in the rat brain. This angiotensin receptor subtype has been termed AT4 and is prominently distributed in cerebral cortex, piriform cortex, hippocampus, habenulae, colliculi, septum, periaqueductal gray, several thalamic nuclei, the arcuate nucleus of the hypothalamus and cerebellum. In the second part of the present investigation, separate groups of rats received i.c.v. injections of angiotensin II (AngII), AngIV or artificial cerebrospinal fluid (aCSF) and were euthanized 2 h later for the purpose of evaluating for brain c-Fos expression. After i.c.v.-injected AngIV, Fos-like immunoreactivity was present in the hippocampus and piriform cortex. This immunoreactivity was unaffected by i.c.v. pretreatment with the AT1 angiotensin receptor antagonist DuP 753 (losartan) or the AT2 receptor ligand PD123177 but was blocked by the AT4 angiotensin receptor antagonist, divalanal-AngIV. I.c.v. injection of AngII resulted in Fos-like immunoreactivity in the dorsal third and lateral ventricles, subfornical organ, lateral hypothalamus and amygdala. Pretreatment with losartan or PD123177 significantly interfered with this AngII-induced immunoreactivity while divalanal-AngIV did not. These results indicate that in both guinea pig and rat brains the AT4 receptor has a distribution different than that previously reported for AT1 and AT2 receptor subtypes. The c-Fos expression results suggest that different brain neuronal pathways are activated by i.c.v. injection of AngII and AngIV.

Angiotensin II

Angiotensin II(3-8) (ANG IV) hippocampal binding: potential role in the facilitation of memory.

The present research characterizes a newly discovered ANG II(3-8) (ANG IV) binding site localized in structures associated with memory function (hippocampus, neocortex, cerebellum), as well as other brain stem structures (thalamus, inferior olivary nucleus). This site is not the AT1 or AT2 site that binds angiotensins II (ANG II) and III (ANG III) nor does it bind the nonpeptide AT1 or AT2 receptor antagonists DuP753 and PD123177, respectively. The intracerebroventricular (ICV) infusion of ANG IV was ineffective at inducing drinking in rats as compared with equivalent doses of ANG II and III. Although not as effective as ANG II or ANG III, ICV infusion of ANG IV did provoke a pressor response at the highest dose (100 pmol/min), which appeared to be mediated by ANG II (AT1)-type receptors and not the specific AIV binding site described here. By contrast, the ICV infusion of ANG IV resulted in greater effects upon retention and retrieval of a passive avoidance task as compared with ANG II. Specifically, ANG II was not different from the ICV infusion of artificial cerebrospinal fluid, while ANG IV improved retention and retrieval of this task.

Angiotensin II

Clinical engineering in a downsizing environment.

Hospitals are currently facing cost-cutting pressures. To meet the challenge, some hospitals have downsized by reducing costs and by promoting new lines of business. In this environment, clinical engineers may need a proactive strategy to maintain the integrity of their service, demonstrate its value, and develop new business opportunities including shared-service maintenance, technology assessment, microcomputer applications, and training.

Biomedical Engineering

Clinical engineering: an in-depth review of its economic potential.

Clinical Engineers are currently employed in hospitals to see that the more complex instrumentation is electrically safe and well maintained. Such an objective fails to capitalize on the economic advantages which can be derived from specialist management. This paper proposes that the objective be broadened to cover the application of engineering technology for lower cost-higher quality health care. The functions involved and the staff needed to attain this objective are analyzed, together with the modus operandi for selecting and integrating cost-effective equipment, designing practical maintenance programs, and training the staff to avoid equipment abuse. Details of recent equipment-oriented malpractice suits are reviewed to identify already proven vulnerable areas. The results achieved from this approach at a 450-bed University Hospital show an estimated reduction of from $144 to $59 for the average cost of a repair, and an overall 60 per cent cost saving in the handling of the biomedical electronic equipment.

Biomedical Engineering